| Literature DB >> 28125669 |
Kejian Wang1, Vikrant Vijay1, James C Fuscoe1.
Abstract
Stably Expressed Genes (SEGs) whose expression varies within a narrow range may be involved in core cellular processes necessary for basic functions. To identify such genes, we re-analyzed existing RNA-Seq gene expression profiles across 11 organs at 4 developmental stages (from immature to old age) in both sexes of F344 rats (n = 4/group; 320 samples). Expression changes (calculated as the maximum expression / minimum expression for each gene) of >19000 genes across organs, ages, and sexes ranged from 2.35 to >109-fold, with a median of 165-fold. The expression of 278 SEGs was found to vary ≤4-fold and these genes were significantly involved in protein catabolism (proteasome and ubiquitination), RNA transport, protein processing, and the spliceosome. Such stability of expression was further validated in human samples where the expression variability of the homologous human SEGs was significantly lower than that of other genes in the human genome. It was also found that the homologous human SEGs were generally less subject to non-synonymous mutation than other genes, as would be expected of stably expressed genes. We also found that knockout of SEG homologs in mouse models was more likely to cause complete preweaning lethality than non-SEG homologs, corroborating the fundamental roles played by SEGs in biological development. Such stably expressed genes and pathways across life-stages suggest that tight control of these processes is important in basic cellular functions and that perturbation by endogenous (e.g., genetics) or exogenous agents (e.g., drugs, environmental factors) may cause serious adverse effects.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28125669 PMCID: PMC5268456 DOI: 10.1371/journal.pone.0170813
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Study design and gene expression stability.
(A) 320 organ samples were collected from rats of different ages and sexes. (B) A total of 19343 unique genes with Entrez ID were refined from 40059 transcripts. The distribution of expression changes demonstrated the rarity of genes with low variation across samples.
Fig 2Numbers of stably expressed genes at different thresholds of expression fold-change and numbers of highest and lowest expressed samples removed.
(A) Cutoff criteria of expression changes of ≤3-fold. (B) Cutoff criteria of expression changes of ≤4-fold. (C) Cutoff criteria of expression changes of ≤5-fold.
KEGG pathways significantly enriched in SEGs.
| KEGG Pathway Term | SEGs Associated with the Pathway | OR | Adjusted P-value |
|---|---|---|---|
| Proteasome | Psmc4; Psma4; Psma3l; Psmd11; Psmd13; Psmb1; Psmd3; Psmd6; Psmd4; Psma1; Psmd12; Psmb4; Psmc1; Psmd1; Psmd7; Psma5 | 41.52 | 1.78 x 10−16 |
| Ubiquitin mediated proteolysis | Ube2d3; Uba3; Cul1; Rbx1; Ube4a; Ube3c; Anapc5; Ddb1; Ube3a; Itch; Birc6; Keap1; Klhl9 | 8.01 | 6.41 x 10−6 |
| RNA transport | Nmd3; Snupn; Eif3s10; Eif4g1; Eif3c; Elac2; Eif2b5; Eif4g2_predicted; Eif4b; Ranbp2; Eif3h | 5.91 | 5.10 x 10−4 |
| Epstein-Barr virus infection | Psmc4; RGD1561926; Psmd11; Psmd13; Psmd3; Psmd6; Psmd4; Psmd12; Psmc1; Polr2b; Psmd1; Psmd7 | 4.79 | 1.17 x 10−3 |
| Aminoacyl-tRNA biosynthesis | Nars2; Farsb; Tars2; Zmat2; Sars; Lars | 11.66 | 1.35 x 10−3 |
| Protein processing in endoplasmic reticulum | Sar1a; Rad23b; Ube2d3; LOC685144; Nsfl1c; Cul1; Rbx1; Edem3; Dnajc10; Vcp | 4.90 | 3.25 x 10−3 |
| Legionellosis | Sar1a; Arf1; Sec22b; Rab1; Vcp | 7.41 | 3.15 x 10−2 |
| Spliceosome | Cwc15; Cdc5l; RGD1561926; Syf2; Prpf8; Plrg1; Prpf6 | 4.53 | 4.35 x 10−2 |
SEGs with expression changes of ≤4-fold–the number of genes in stably expressed pathways increases with relaxed selection criteria.
| Number of Genes in KEGG Pathways at Expression Change of ≤4-fold Calculated after Removal of N Highest and Lowest Expressed Samples | ||||||
|---|---|---|---|---|---|---|
| KEGG Pathway Term | N = 0 | N = 1 | N = 2 | N = 3 | N = 4 | Adjusted p-values |
| Proteasome | 8 | 16 | 19 | 20 | 24 | 3.5 x 10−7–10−21 |
| Ubiquitin mediated proteolysis | 8 | 13 | 15 | 15 | 18 | 8.7 x 10−3–6.4 x 10−6 |
| RNA transport | 8 | 11 | 12 | 15 | 16 | 1.2 x 10−3–3 x 10−4 |
| Aminoacyl-tRNA biosynthesis | 6 | 8 | 9 | 15 | 1.4 x 10−3–3 x 10−10 | |
| Protein processing in endoplasmic reticulum | 10 | 12 | 17 | 19 | 3 x 10−3–6 x 10−5 | |
| Spliceosome | 7 | 12 | 13 | 4 x 10−2–2 x 10−3 | ||
| Protein export | 5 | 6 | 8 | 3 x 10−3–2 x 10−5 | ||
| Legionellosis | 5 | 6 | 6 | 7 | >10−2 | |
| mTOR signaling pathway | 6 | 8 | 8 | >10−2 | ||
| Nucleotide excision repair | 5 | >10−2 | ||||
| Renal cell carcinoma | 6 | >10−2 | ||||
| AMPK signaling pathway | 10 | 11 | >10−2 | |||
| SNARE interactions in vesicular transport | 5 | 6 | >10−2 | |||
| Insulin signaling pathway | 10 | >10−2 | ||||
| Regulation of autophagy | 5 | >10−2 | ||||
Fig 3Expression stability of human homologs of SEGs.
Each bar represented a gene, with the height corresponding to the expression change (maximum expression–minimum expression). The SEG homologs are red and those associated with significant pathways identified in Table 1 are marked with a blue dot.
The association between SEGs knockout and lethal phenotypes.
| SEG Homologs | Other Genes | |
|---|---|---|
| 15 | 421 | |
| 1 | 920 | |
| 32.78 (4.32 ~ 248.97) | ||
| 3.84 × 10−7 | ||
a P-value was determined with two-tailed Fisher’s exact test.
Summary of SEGs with lethal knockout phenotypes.
| Lethal Knockout Mouse Gene | Corresponding Rat SEG | Gene Name | NCBI Gene Summary |
|---|---|---|---|
| Alg10b | Alg10b | ALG10, alpha-1,2-glucosyltransferase | Regulatory component of non-inactivating K+ channels |
| Chd4 | Chd4 | Chromodomain helicase DNA binding protein 4 | Member of the CHD protein family; may play a role in chromatin reorganization; may play a role in osmosignalling |
| Cog3 | Cog3 | Component of oligomeric golgi complex 3 | |
| Eif4g2 | Eif4g2 (predicted) | Eukaryotic translation initiation factor 4, gamma 2 | This gene product functions as a general repressor of translation by forming translationally inactive complexes |
| Exoc8 | Exoc8 | Exocyst complex component 8 | Encodes a subunit of the exocyst complex, an exocytosis-associated complex specifically located at sites of vesicle fusion |
| Lztr1 | Lztr1 | Leucine-zipper-like transcription regulator 1 | |
| Maea | Maea | Macrophage erythroblast attacher | |
| Mapkap1 | Mapkap1 | Mitogen-activated protein kinase associated protein 1 | |
| Ppp4r2 | Ppp4r2 | Protein phosphatase 4, regulatory subunit 2 | |
| Raf1 | Raf1 | V-raf-leukemia viral oncogene 1 | Acts as a mitogenic protein kinase; mutant forms may play a role in transformation |
| Rint1 | RGD1560433 | RAD50 interactor 1 | |
| Sec22b | Sec22b | SEC22 homolog B, vesicle trafficking protein | |
| Usp36 | Usp36 | Ubiquitin specific peptidase 36 | |
| Usp5 | Usp5 | Ubiquitin specific peptidase 5 | |
| Vps13d | Vps13d | Vacuolar protein sorting 13 homolog D |
Fig 4Human homolog genes of SEGs showed significantly lower Genetic Damage Index (GDI).
Each bar represented a gene, with the height corresponding to the GDI value. The SEG homologs are red and those associated with significant pathways identified in Table 1 are marked with a blue dot.
| SEG Homologs | Other Genes | |
| In category | ||
| Not in category |